Clinical Overview
Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administered solely by healthcare professionals by deep intramuscular injection or intravenous injection/infusion over 30 minutes after reconstitution with sterile diluent.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Local injection site pain/phlebitis, diarrhea, nausea, pruritus, transient transaminitis. Rare/Severe: Encephalopathy, myoclonus, asterixis, and seizures in patients with unadjusted renal impairment; anaphylaxis; and Clostridioides difficile colitis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in cephalosporin allergy. Exercise caution in penicillin-allergic patients. Dosage must be reduced in patients with renal impairment to avoid neurotoxicity.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Ceftazidime Injection 250mg
Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.
Ceftazidime Injection 500mg
Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.
Ceftazidime 250mg + Tazobactum 31.25mg Injection
Ceftazidime and Tazobactam is a parenteral combination designed to combat resistant Pseudomonas aeruginosa and beta-lactamase-producing Enterobacteriaceae. Ceftazidime provides high intrinsic anti-pseudomonal bactericidal activity, while tazobactam inhibits beta-lactamases that would otherwise hydrolyze the cephalosporin ring. Indicated for nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and severe urinary tract infections.
Ceftazidime 1000 mg + Tazobactum 125 mg Injection
Ceftazidime and Tazobactam is a parenteral combination designed to combat resistant Pseudomonas aeruginosa and beta-lactamase-producing Enterobacteriaceae. Ceftazidime provides high intrinsic anti-pseudomonal bactericidal activity, while tazobactam inhibits beta-lactamases that would otherwise hydrolyze the cephalosporin ring. Indicated for nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and severe urinary tract infections.